Safety and Efficacy Study of Artificial Cornea (AuroKPro)

This study is currently recruiting participants.
Verified July 2011 by Aurolab
Sponsor:
Information provided by (Responsible Party):
Aurolab
ClinicalTrials.gov Identifier:
NCT01018888
First received: November 24, 2009
Last updated: January 7, 2013
Last verified: July 2011

November 24, 2009
January 7, 2013
August 2010
June 2014   (final data collection date for primary outcome measure)
Visual Acuity [ Time Frame: 1st Month, 2nd Month, 3rd Month,5th Month, 7th Month, 9th Month and 12th Month ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01018888 on ClinicalTrials.gov Archive Site
Retention of the device [ Time Frame: 1st Month, 2nd Month, 3rd Month,5th Month, 7th Month, 9th Month and 12th Month ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety and Efficacy Study of Artificial Cornea
Clinical Assessment of Auro KPro

The purpose of this study is to evaluate the stability of artificial cornea manufactured by Aurolab and to assess its visual outcomes.

The keratoprosthesis, also know as an artificial cornea plays a significant role in combating corneal blindness in patients who are no longer candidates for penetrating keratoplasty.The global incidence of corneal blindness is estimated to be 6-8 million. In India there are approximately 6.8 million cases of unilateral corneal blindness and 1.3 million people with bilateral corneal pathology.

Eligible subjects after getting informed consent will be included in this study. All the subjects will have pre-operative evaluation which includes history, visual acuity, Intraocular pressure (IOP), evaluation of tear film and ultrasound A and B scan. Ocular inflammation will be controlled prior to surgery. Keratoplasty will be performed with keratoprosthesis under local anesthesia. Patients will be followed up at regular interval to assess the outcome variables.

Interventional
Phase 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Corneal Transplantation
Device: Auro KPro (Keratoprosthesis)
Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
Other Name: Auro KPro
Experimental: Keratoprosthesis
Intervention: Device: Auro KPro (Keratoprosthesis)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
July 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age more than 20 years
  • Willing to participate and review on schedule
  • Multiple failed grafts with poor prognosis for regrafting
  • Adequate tear film and lid function
  • Projection of light in all quadrants
  • Bilateral blind

Exclusion Criteria:

  • Reasonable chance of success with keratoplasty
  • Autoimmune disease such as Stevens Johnson Syndrome, Pemphigoid
  • End stage glaucoma
  • Retinal detachment
Both
20 Years to 80 Years
No
Contact: Mr.Karthikumar S, M.Pharm 0452-3096100 ext 229 crd@aurolab.com
Contact: Elakiya S, M.Sc 0452-4356100 ext 364 sicca@aravind.org
India
 
NCT01018888
1PN1010941
Yes
Aurolab
Aurolab
Not Provided
Principal Investigator: Dr. Jeena Mascarenhas, MBBS, MS Aravind Eye Hospital, Madurai
Aurolab
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP